Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
- Registration Number
- NCT06717958
- Lead Sponsor
- Technische Universität Dresden
- Brief Summary
maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days
- Detailed Description
Determination of the efficacy of Ivosidenib to improve event-free survival when given as maintenance therapy following alloSCT.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Ivosidenib Ivosidenib 250 MG (milligram) -
- Primary Outcome Measures
Name Time Method event-free survival 24 months
- Secondary Outcome Measures
Name Time Method